Fever News and Research RSS Feed - Fever News and Research

Martindale Pharma announces UK launch of Prenoxad Injection for opioid overdose

Martindale Pharma announces UK launch of Prenoxad Injection for opioid overdose

Martindale Pharma, a leader in the manufacture and supply of specialty pharmaceuticals, is pleased to announce the UK launch of Prenoxad Injection, the world's first licensed emergency treatment for acute opioid related overdose for use at home or other non-medical settings. [More]
New approach could democratize viral surveillance, says UCSF scientist

New approach could democratize viral surveillance, says UCSF scientist

The tick-borne Lone Star virus has been conclusively identified as part of a family of other tick-borne viruses called bunyaviruses, which often cause fever, respiratory problems and bleeding, according to new research led by scientists at UC San Francisco. [More]
H7N9 bird flu virus continues to spread throughout China

H7N9 bird flu virus continues to spread throughout China

"China on Saturday reported its first case of H7N9 bird flu in the southern province of Hunan, the latest sign the virus that has killed 23 people in the country is continuing to spread," Reuters reports (Ruwitch, 4/29). [More]
Collaborative research network to understand spread of infectious diseases

Collaborative research network to understand spread of infectious diseases

The Models of Infectious Disease Agent Study is a collaborative research network funded by the National Institutes of Health that uses computational, statistical and mathematical models to understand the spread of infectious diseases such as influenza, pertussis, West Nile disease, dengue fever and cholera. [More]

Children born outside U.S. have lower prevalence of allergic disease

A study by Jonathan I. Silverberg, M.D., Ph.D., M.P.H., of St. Luke's—Roosevelt Hospital Center, New York, and colleagues suggests children living the in the United States but born outside the U.S. have a lower prevalence of allergic disease that increases after residing in the United States for one decade. [More]
Forecasting outbreak of dengue fever with warning system

Forecasting outbreak of dengue fever with warning system

With the help of a warning system which measures the risk of dengue incidence using precipitation and air temperature, it is possible to forecast the outbreak of dengue fever up to 16 weeks in advance. [More]
Pfizer reports that Prevenar 13 Phase 3 study meets all primary, secondary objectives

Pfizer reports that Prevenar 13 Phase 3 study meets all primary, secondary objectives

Pfizer Inc. presented today the results from a Phase 3 study investigating immunogenicity, tolerability and safety of Prevenar 13 (Pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]) in adults 18 to 49 years of age. [More]
Antihistamine drugs work by preventing histamine from attaching to H1 receptors

Antihistamine drugs work by preventing histamine from attaching to H1 receptors

Itchy eyes, scratchy throat, running nose--it's allergy season! What triggers these allergic reactions, and how do allergy medications work? [More]
Researchers call H7N9 bird flu strain 'one of the most lethal'; first case outside China reported by Taiwan

Researchers call H7N9 bird flu strain 'one of the most lethal'; first case outside China reported by Taiwan

Chinese scientists have confirmed for the first time that a new strain of bird flu that has killed 23 people in China has been transmitted to humans from chickens. [More]
H7N9 flu virus found to transmit from birds to humans but not person-to-person

H7N9 flu virus found to transmit from birds to humans but not person-to-person

Scientists in China have confirmed for the first time that the influenza A H7N9 virus has transmitted from birds—specifically, chicken at a wet poultry market—to humans, according to an Article published Online First in The Lancet. [More]
Vertex presents data of telaprevir Phase 3b CONCISE study in people with genotype 1 chronic HCV

Vertex presents data of telaprevir Phase 3b CONCISE study in people with genotype 1 chronic HCV

Vertex Pharmaceuticals Incorporated today announced new data from an interim analysis of the exploratory global Phase 3b CONCISE study evaluating the potential to shorten total treatment with telaprevir combination therapy to 12 weeks in certain people with genotype 1 chronic hepatitis C virus infection who have the IL28B CC genotype. [More]

Research maps risk factors for transmission of animal brucellosis, BTB to humans

A new study at the Institute of Tropical Medicine in Antwerp analyses the impact of animal brucellosis and bovine tuberculosis on animals and people in urban, peri-urban and rural Niger. [More]
Study: Nearly two-thirds of children receiving stem cell transplants return to hospital within six months

Study: Nearly two-thirds of children receiving stem cell transplants return to hospital within six months

Nearly two-thirds of children receiving stem cell transplants returned to the hospital within six months for treatment of unexplained fevers, infections or other problems, according to a study performed at Dana-Farber/Children's Hospital Cancer Center in Boston. [More]
Janssen announces safety results from two Phase 3 studies of simeprevir in hepatitis C patients

Janssen announces safety results from two Phase 3 studies of simeprevir in hepatitis C patients

Janssen R&D Ireland today announced primary efficacy and safety results from two global Phase 3 studies demonstrating that use of the investigational protease inhibitor simeprevir (TMC435) led to sustained virologic response 12 weeks after the end of treatment (SVR12) in 80 and 81 percent, respectively, of treatment-naive genotype 1 chronic hepatitis C adult patients with compensated liver disease, including all stages of liver fibrosis, when administered once daily with pegylated interferon and ribavirin. [More]

Clinical data on simeprevir for treatment of hepatitis C patients to be presented at EASL meeting

Medivir AB today announces that data will be presented on the investigational protease inhibitor simeprevir (TMC435) for the treatment of genotype 1 hepatitis C patients. [More]
Nuvo Research reaches another milestone with the launch of Pliaglis in Europe

Nuvo Research reaches another milestone with the launch of Pliaglis in Europe

Nuvo Research Inc., a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and Galderma Pharma, S.A., today announced the European launch of Pliaglis (lidocaine and tetracaine) Cream 7%/7%. [More]
ViroPharma announces results of VP20621 Phase 2 study for preventing recurrent CDI

ViroPharma announces results of VP20621 Phase 2 study for preventing recurrent CDI

ViroPharma Incorporated, an international biopharmaceutical company committed to developing and commercializing innovative products that address unmet medical needs and rare diseases, today announced the results of a Phase 2 study of VP20621 (non-toxigenic Clostridium difficile; NTCD) a novel treatment approach for preventing recurrent C. difficile infections. [More]

Romark Laboratories starts NT-300 Phase 3 trial for treatment of acute uncomplicated influenza

Romark Laboratories announced that it has begun enrolling patients in a global Phase 3 clinical trial of NT-300 (nitazoxanide) for treatment of acute uncomplicated influenza. [More]
Pediatric allergist offers tips to protect kids from allergies during the spring

Pediatric allergist offers tips to protect kids from allergies during the spring

Spring is having a hard time deciding if it wants to be here this year. Still, for many allergy sufferers its presence is being felt. Allergies are extremely common with an estimated 50 million people in the United States suffering from them. [More]

Scientists working on pollen count map to warn hay fever sufferers

In future there could be precise, personal travel warnings for hay fever sufferers covering the whole of Europe. The pollen warning service of the MedUni Vienna is working on a pollen count map in order to be better able to warn hay fever sufferers. [More]